The PolyPeptide Group, a
global Contract Development and Manufacturing Organization (CDMO) for Peptide,
Peptidomimetic and other Drug Substances, has announced that it has partnered
with Novavax Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing
next-generation vaccines for serious infectious diseases, on large-scale GMP
production of a critical component of Novavax’ novel coronavirus vaccine
candidate, NVX-CoV2373.
PolyPeptide Group will produce two key intermediates used in the production of
Matrix-M™, the adjuvant component of the vaccine,
which is being used to enhance the vaccine’s immune response and stimulate high
levels of neutralizing antibodies.
NVX-CoV2373 is a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology.
“The
experience and expertise that PolyPeptide applies for the production of peptides, is ideally
suited for the production of our key intermediate components of Matrix-M™,”
said Novavax Senior Vice President, Process Technology, Timothy J. Hahn, “The PolyPeptide Group is an important strategic partner in expanding
our commercial supply chain of
adjuvant for our vaccines.”
“PolyPeptide is delighted to be supporting Novavax’ global supply chain to enable
the large-scale production of Novavax’ saponin-based Matrix-M™ adjuvant across
our facility network” says Group Commercial Director, Neil Thompson. “Our
Global organization is engaged with Novavax to successfully fight this global pandemic.”
About PolyPeptide
The PolyPeptide Group is a
privately-held Contract Development & Manufacturing Organization (CDMO)
which focuses primarily on proprietary and generic GMP-grade peptides for the
diagnostic, cosmetic, pharmaceutical and biotechnological market.
The
Group has manufacturing facilities in Belgium, Sweden, France, India and two
sites in the USA. As a multinational company with more than 850 employees
worldwide, its diversity brings breadth and depth of knowledge and experience
to the Group. The PolyPeptide
Group has grown by selective acquisition of existing expertise, culminating in
its position today as a leader in peptide manufacturing.
For
more information, visit www.polypeptide.com
About Matrix-M™
Novavax’
patented saponin-based Matrix-M adjuvant has demonstrated a potent and
well-tolerated effect by stimulating the entry of antigen-presenting cells into
the injection site and enhancing antigen presentation in local lymph nodes,
boosting immune response and helping an immunized person make antibodies
against the virus.
About Novavax
Novavax,
Inc. (Nasdaq:NVAX), is a late-stage biotechnology company that promotes
improved health globally through the discovery, development, and
commercialization of innovative vaccines to prevent serious infectious
diseases.
Novavax
recently initiated development of NVX-CoV2373, its vaccine candidate against
SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results
expected in July of 2020.
NanoFlu™,
its quadrivalent influenza nanoparticle vaccine, met all primary objectives in
its pivotal Phase 3 clinical trial in older adults.
Both
vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™
adjuvant in order to enhance the immune response and stimulate high levels of
neutralizing antibodies. Novavax is a leading innovator of recombinant
vaccines; its proprietary recombinant technology platform combines the power
and speed of genetic engineering to efficiently produce highly immunogenic
nanoparticles in order to address urgent global health needs.
Learn
more at www.novavax.com.
The PolyPeptide Group is a privately-held Contract Development & Manufacturing Organization (CDMO) who focuses on proprietary and generic GMP-grade peptides for the diagnostic, cosmetic, pharmaceutical and biotechnological market. The Group has manufacturing facilities in Belgium, Sweden, France, India and two sites in the USA. As a multinational company with more than 850 employees worldwide, its diversity brings breadth and depth of knowledge and experience to the Group. The PolyPeptide Group has grown by selective acquisition of existing expertise, culminating in its position today as a leader in peptide manufacturing.
LINK:
https://www.mynewsdesk.com/polypeptide-laboratories-sweden-ab/pressreleases/polypeptide-group-selected-by-novavax-to-manufacture-critical-intermediates-of-matrix-m-adjuvant-for-its-covid-19-vaccine-3005178?utm_campaign=send_list